Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02983799 · ClinicalTrials.gov registry record · Phase 2
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
A Phase 2 study of Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
- 20
- Study locations
NCT02983799 is a Phase 2 study of Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity that has completed, run by AstraZeneca. The registered enrollment target is 272 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT02983799, a Phase 2 study of Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian cancer. Subjects should have received at least 1 prior line of platinum-based chemotherapy.
Conditions Studied
Interventions
- DRUG OLAPARIB
Study Locations (20)
New Jersey
- Research Site - Berkeley Heights
- Research Site - Hackensack
- Research Site - Newark
- Research Site - Teaneck
California
- Research Site - La Jolla
- Research Site - Los Angeles
Connecticut
- Research Site - Hartford
- Research Site - New Haven
Michigan
- Research Site - Detroit
- Research Site - Detroit
Minnesota
- Research Site - Minneapolis
- Research Site - Saint Paul
Alaska
- Research Site - Anchorage
Colorado
- Research Site - Aurora
Delaware
- Research Site - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2020-12-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02983799
The ClinicalTrials.gov registry entry for NCT02983799 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity appearing as the primary indexed condition, and to 1 intervention - of which OLAPARIB is the first listed.
NCT02983799 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New Jersey, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02983799 about?
NCT02983799 is a clinical study titled "Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status". This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian cancer. Subjects should have received at...
What is the current status of trial NCT02983799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2016-12-22. Estimated completion is 2020-12-03.
What conditions does trial NCT02983799 study?
This clinical trial studies the following conditions: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity.
What interventions are being tested in trial NCT02983799?
The interventions under investigation include: OLAPARIB (DRUG).
Who is sponsoring clinical trial NCT02983799?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02983799 being conducted?
This trial has 20 study locations across Alaska, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.